NCT00976612已完成不适用
Pharmacokinetic Study of Nilotinib in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Showing Failure to Both Imatinib and Sunitinib
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- nilotinib pharmacokinetics
研究概览
简要总结
In patients who are receiving nilotinib, nilotinib plasma levels will be measured after 1 month of nilotinib treatment. The relationship between surgery type and nilotinib pharmakokinetic properties will be investigated in this study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with metastatic or unresectable gastrointestinal stromal tumor
- •Patients receiving nilotinib after failure to imatinib and sunitinib
排除标准
- 未提供
研究组 & 干预措施
Nilotinib
Patients who receive nilotinib with failure to both imatinib and sunitinib
干预措施: Nilotinib (Drug)
结局指标
主要结局
nilotinib pharmacokinetics
时间窗: Up to 3years
次要结局
未报告次要终点
研究者
Yoon-Koo Kang
Professor
Asan Medical Center
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Clinical Trial to Evaluate the Effect of Nilotinib on the PK/PD of MeforminHealthyNCT04448821Hyewon Chung16
已完成
1 期
To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of NilotinibChronic Myeloid LeukemiaNCT01223898Novartis Pharmaceuticals19
已完成
4 期
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal ResponsePhiladelphia Chromosome PositiveChronic Myelogenous Leukemia in Chronic PhaseNCT01043874Novartis Pharmaceuticals45
已完成
3 期
Nilotinib in PH+, BCR-, ABL+ CML PatientsChronic Myeloid LeukemiaNCT01535391Gruppo Italiano Malattie EMatologiche dell'Adulto109
招募中
2 期
Clinical study evaluating efficacy of Nilotinib in CML patientsChronic myelogenous leukemiaJPRN-UMIN000002579ara Hospital Kinki University School Of Medicine20